CBDA and CBC, lesser-known cannabinoids: what are they and what for (table)
CBDA and CBC are lesser-known cannabinoids of cannabis. What has been demonstrated for each of them, on which animals and cells, and what is missing in these studies.
Discussion about cannabis usually starts and ends with CBD and THC. The plant produces over a hundred cannabinoids, some of which have their own distinct biological effects. CBDA and CBC are increasingly appearing on the labels of full-spectrum products and in research summaries, usually with descriptions stronger than the data behind them. This article collects what has actually been demonstrated for both compounds, and for each finding, it states what it was measured on: in cell culture, in rats, in shrews, or in humans. This distinction determines how many of these promises remain. We also show how to recognize a product that actually contains either of these compounds, as the trade name is no clue here.
KEY INFORMATION
• CBDA is the acidic precursor form of CBD, present in the fresh plant; heating removes the carboxyl group and converts it into CBD.
• CBDA does not have a higher affinity for the 5-HT1A receptor than CBD; it has been shown to enhance the activation of this receptor by an agonist and works more strongly than CBD against nausea in rats and vomiting in shrews (Bolognini, Br J Pharmacol, 2013).
• CBC does not stimulate the CB1 receptor but is a selective CB2 agonist with higher efficacy than THC in a cell system (Udoh, Br J Pharmacol, 2019).
• Neither of these compounds has been studied in randomized clinical trials in humans.
• CBD is not an authorized novel food in the European Union, and notifying health authorities of this status does not change it.
What is the difference between CBDA and CBD?
The difference is one chemical group and the way it disappears. A living cannabis plant does not produce CBD directly. It synthesizes cannabidiolic acid, or CBDA, from the parent compound CBGA. Only heating triggers decarboxylation, removes the carboxyl group, and converts CBDA into CBD. This occurs during drying, vaporization, smoking, and baking, which is why processed products usually contain no CBDA at all.
For years, it was treated as an inactive raw material. This image has changed, but it has changed in a narrower scope than product descriptions suggest. The demonstrated effect concerns the serotonin receptor 5-HT1A, not cannabinoid receptors, and does not involve stronger binding to this receptor. In a functional test on rat brainstem membranes, CBDA at concentrations from 0.1 to 100 nanomoles increased the maximum response induced by the agonist 8-OH-DPAT, thus enhancing receptor activation rather than occupying it.
The distinction between acidic and active forms is described more broadly in the post about acidic forms of cannabinoids. It is worth knowing, as it determines whether a given product can even contain what the label promises.
What has actually been demonstrated for CBDA in studies?
The evidence is animal-based and concerns nausea and vomiting. In a study published in British Journal of Pharmacology, CBDA at doses of 0.1 and 0.5 mg per kilogram, administered intraperitoneally to house shrews, limited toxin- and motion-induced vomiting and delayed the first vomiting episode. In rats, CBDA at doses of 0.01 and 0.1 mg per kilogram suppressed the aversive reaction induced by lithium chloride, and the effect was negated by the 5-HT1A receptor antagonist. The CB1 receptor antagonist did not change anything, confirming that the pathway runs outside the cannabinoid system (Bolognini, Br J Pharmacol, 2013).
The authors compared CBDA with CBD and found that it acts significantly stronger, both in inhibiting vomiting and in enhancing the activation of the 5-HT1A receptor. This is a real result and there is no reason to downplay it. However, it has two limitations that supplement descriptions remain silent about: it concerns animal species in which vomiting can be modeled, and intraperitoneal administration, not oral.
No randomized clinical trial with CBDA in humans has been published. Thus, the statement “CBDA alleviates nausea” describes the result in rats and shrews, not a clinical finding. No one has performed a translation to an oral dose in humans.
What is known about CBC?
CBC, or cannabichromene, is produced in the plant from cannabichromenic acid, which comes from the same parent compound as CBDA. The distinctiveness of CBC lies in the fact that it targets different goals than CBD. A study in British Journal of Pharmacology showed that in cells with human cannabinoid receptors, CBC stimulates CB2 but does not stimulate CB1, and its efficacy against CB2 is higher than that of THC. Continuous presence of the compound led to a decrease in CB2 receptors on the cell surface and a dampening of the response (Udoh, Br J Pharmacol, 2019).
The lack of action on CB1 is the reason why CBC does not intoxicate; this receptor is responsible for the psychoactivity of THC. The distribution of both receptors is described in the post about CB1 and CB2 receptors.
The second described mechanism is the inhibition of endocannabinoid deactivation and stimulation of the TRPA1 channel. Caution should be exercised here, as the work that cites this description as background also checked its effects and the result was mixed: in mice, CBC normalized accelerated peristalsis induced by inflammation but did not change motility in healthy animals, and in an ex vivo study, it did not change endocannabinoid concentrations in the tissue at all. The actions were not negated by either cannabinoid receptor antagonists or the TRPA1 antagonist (Izzo, Br J Pharmacol, 2012). The mechanism is therefore open, not established.
How do temperature and light affect CBDA and CBC?
CBDA is thermally unstable by definition, as its conversion to CBD is a reaction that occurs under heat. Any process involving heating, such as vaporization, cooking, and extraction at elevated temperatures, shifts the product profile towards CBD. Preserving CBDA requires unheated raw material and cold extraction.
| Feature | CBDA | CBC | CBD for comparison |
|---|---|---|---|
| Full name | cannabidiolic acid | cannabichromene | cannabidiol |
| Pathway of formation in the plant | from CBGA | from CBGA through CBCA | from CBDA after decarboxylation |
| CB1 receptor | no significant action | does not stimulate | weak action |
| Described molecular target | enhancing activation of 5-HT1A | agonism of CB2, TRPA1 channel | 5-HT1A, TRPV1, FABP proteins |
| Measured on | rats, shrews, binding tests | cell lines, mice | clinical studies in humans |
| Stability in heat | low, converts to CBD | higher than CBDA | high |
The second factor changing the cannabinoid profile over time is light, which is why oils are sold in dark bottles. A product sitting for months in a transparent package may have lower concentrations than stated in the analytical certificate prepared just after production. Storage conditions are discussed in detail in the post about storing CBD oil.
How to recognize a product containing CBDA or CBC?
The analytical certificate decides, not the trade name. The terms “raw” and “unrefined” suggest the preservation of the acidic form, but in themselves guarantee nothing. A certificate with a full cannabinoid profile shows whether CBDA or CBC has been detected at all and in what quantity. CBD isolate-based products contain neither, as isolation removes everything except one molecule.
It is also worth remembering the legal status. CBD is not an authorized novel food in the European Union, and submitting a health notification does not change this status. The EFSA panel has established a provisional safe dose of 0.0275 mg per kilogram of body weight per day, which is about 2 mg daily for a person weighing 70 kg, and noted that safety cannot be established for individuals under 25 years of age, pregnant or breastfeeding women, and those taking medications (EFSA, EFSA Journal, 2026).
For CBC itself, the picture is even more cautious. A 2024 review notes that products with this cannabinoid have entered the retail market and are widely used with little evidence of their safety and efficacy or none at all (Sepulveda, J Pharmacol Exp Ther, 2024). In the store at Bucha, you will find strains rich in CBD and CBG in the hemp flower category; the content of acidic forms and rarer cannabinoids can only be read from the laboratory report of a specific batch.
Frequently Asked Questions
What is the difference between CBDA and CBD?
CBDA is the acidic precursor form of CBD, present in the fresh, unheated plant. Heating removes the carboxyl group and converts it into CBD. CBDA has its own effects: it enhances the activation of the serotonin receptor 5-HT1A and in animal models inhibits vomiting more strongly than CBD.
Does CBDA alleviate nausea in humans?
This has not been studied. The results come from rats and house shrews, to whom the compound was administered intraperitoneally in doses of fractions of a milligram per kilogram (Bolognini, Br J Pharmacol, 2013). No randomized clinical trial with CBDA in humans has been published.
Are CBDA and CBC psychoactive?
No. Neither of these compounds stimulates the CB1 receptor, which is responsible for the intoxicating effects of THC. CBC, on the other hand, stimulates the CB2 receptor, mainly present in immune system cells, which does not produce a psychoactive effect.
Does CBC raise anandamide levels?
CBC is described as a compound that inhibits the deactivation of endocannabinoids, but a study investigating this pathway in the intestines of mice found no change in endocannabinoid concentrations in the tissue, and the effects of CBC were not negated by cannabinoid receptor antagonists or the TRPA1 antagonist. The mechanism remains open.
How to check if a product contains CBDA or CBC?
Only through an analytical certificate with a full cannabinoid profile. The names “raw” and “full spectrum” are not guarantees. CBD isolate-based products do not contain either of these compounds, as the isolation process removes everything except one molecule.
This article is for informational and educational purposes only and does not constitute medical advice. Before starting to use cannabis or CBD for therapeutic purposes, consult a doctor, especially if you are taking other medications, are pregnant, or breastfeeding.
Author: Michał Waluk · Published: 2026-07-03 · Updated: 2026-08-16
